In all , 5 ( 62.5 % ) dexmedetomidine patients and 1 ( 12.5 % ) midazolam patient manifested ASD ( P = .063 ) , and 1 dexmedetomidine patient and 5 midazolam patients developed new-onset delirium ( P = .07 ) .